These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15354329)

  • 1. Association of CCR5 delta32 deletion with early death in multiple sclerosis.
    Gade-Andavolu R; Comings DE; MacMurray J; Rostamkhani M; Cheng LS; Tourtellotte WW; Cone LA
    Genet Med; 2004; 6(3):126-31. PubMed ID: 15354329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis.
    Kantarci OH; Morales Y; Ziemer PA; Hebrink DD; Mahad DJ; Atkinson EJ; Achenbach SJ; De Andrade M; Mack M; Ransohoff RM; Lassmann H; Bruck W; Weinshenker BG; Lucchinetti CF
    J Neuroimmunol; 2005 Dec; 169(1-2):137-43. PubMed ID: 16182378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis.
    Kaimen-Maciel DR; Reiche EM; Brum Souza DG; Frota Comini ER; Bobroff F; Morimoto HK; Ehara Watanabe MA; Carvalho De Oliveira J; Matsuo T; Lopes J; Donadi EA
    Int J Mol Med; 2007 Sep; 20(3):337-44. PubMed ID: 17671738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemokine receptor V Δ32 deletion in multiple sclerosis patients in Csongrád County in Hungary and the North-Bácska region in Serbia.
    Török N; Molnár K; Füvesi J; Karácsony M; Zsiros V; Fejes-Szabó A; Fiatal S; Ádány R; Somogyvári F; Stojiljković O; Vécsei L; Bencsik K
    Hum Immunol; 2015 Jan; 76(1):59-64. PubMed ID: 25500253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis.
    Pulkkinen K; Luomala M; Kuusisto H; Lehtimäki T; Saarela M; Jalonen TO; Elovaara I
    Acta Neurol Scand; 2004 May; 109(5):342-7. PubMed ID: 15080861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Meta-analysis of the relation between chemokine receptor 5 delta32 polymorphism and multiple sclerosis susceptibility.
    Song GG; Lee YH
    Immunol Invest; 2014; 43(4):299-311. PubMed ID: 24295368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis.
    van Veen T; Nielsen J; Berkhof J; Barkhof F; Kamphorst W; Bö L; Ravid R; Verweij CL; Huitinga I; Polman CH; Uitdehaag BM
    J Neuroimmunol; 2007 Oct; 190(1-2):157-64. PubMed ID: 17884183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.
    Møller M; Søndergaard HB; Koch-Henriksen N; Sorensen PS; Sellebjerg F; Oturai AB
    Acta Neurol Scand; 2014 Jan; 129(1):27-31. PubMed ID: 23668375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association analysis and allelic distribution of deletion in CC chemokine receptor 5 gene (CCR5Δ32) among breast cancer patients of Pakistan.
    Fatima F; Saleem S; Hameed A; Haider G; Ali Zaidi SA; Kanwal M; Zehra S; Azhar A
    Mol Biol Rep; 2019 Apr; 46(2):2387-2394. PubMed ID: 30848448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mutated CCR5 gene may have favorable prognostic implications in MS.
    Kantor R; Bakhanashvili M; Achiron A
    Neurology; 2003 Jul; 61(2):238-40. PubMed ID: 12874407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR5Δ32 - A piece of protection in the inflammatory puzzle of multiple sclerosis susceptibility.
    Troncoso LL; Pontillo A; Oliveira EML; Finkelszteijn A; Schneider S; Chies JAB
    Hum Immunol; 2018 Aug; 79(8):621-626. PubMed ID: 29729320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of CCR5-Delta32 genotype in Spanish population with multiple sclerosis.
    Otaegui D; Ruíz-Martínez J; Olaskoaga J; Emparanza JI; López de Munain A
    Neurogenetics; 2007 Aug; 8(3):201-5. PubMed ID: 17351762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis.
    Sellebjerg F; Madsen HO; Jensen CV; Jensen J; Garred P
    J Neuroimmunol; 2000 Jan; 102(1):98-106. PubMed ID: 10626673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine receptor 5 (CCR5) deletion polymorphism in North Indian patients with coronary artery disease.
    Sharda S; Gilmour A; Harris V; Singh VP; Sinha N; Tewari S; Ramesh V; Agrawal S; Mastana S
    Int J Cardiol; 2008 Feb; 124(2):254-8. PubMed ID: 17383752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the distribution of the CCR5-Δ32 allele in third-generation Maltese citizens to disprove the Black Death hypothesis.
    Baron B; Schembri-Wismayer P
    Int J Immunogenet; 2011 Apr; 38(2):139-43. PubMed ID: 21156032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue.
    Simpson J; Rezaie P; Newcombe J; Cuzner ML; Male D; Woodroofe MN
    J Neuroimmunol; 2000 Aug; 108(1-2):192-200. PubMed ID: 10900353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility.
    Srivastava A; Pandey SN; Choudhuri G; Mittal B
    Scand J Immunol; 2008 May; 67(5):516-22. PubMed ID: 18405329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course.
    Silversides JA; Heggarty SV; McDonnell GV; Hawkins SA; Graham CA
    Mult Scler; 2004 Apr; 10(2):149-52. PubMed ID: 15124759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
    Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
    Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chemokine receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy.
    Panzer U; Schneider A; Steinmetz OM; Wenzel U; Barth P; Reinking R; Becker JU; Harendza S; Zahner G; Fischereder M; Krämer BK; Schlöndorff D; Ostendorf T; Floege J; Helmchen U; Stahl RA
    Kidney Int; 2005 Jan; 67(1):75-81. PubMed ID: 15610230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.